Home > Publications database > High antibody levels against human herpesvirus-6A interact with lifestyle factors in multiple sclerosis development. > print

001     169184
005     20240229133644.0
024 7 _ |a 10.1177/13524585211022011
|2 doi
024 7 _ |a pmid:34124961
|2 pmid
024 7 _ |a 1352-4585
|2 ISSN
024 7 _ |a 1477-0970
|2 ISSN
024 7 _ |a altmetric:107885498
|2 altmetric
037 _ _ |a DKFZ-2021-01308
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Wu, Jing
|b 0
245 _ _ |a High antibody levels against human herpesvirus-6A interact with lifestyle factors in multiple sclerosis development.
260 _ _ |a London
|c 2022
|b Sage
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1648719667_24556
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2022 Mar;28(3):383-392
520 _ _ |a Infection with human herpesvirus 6A (HHV-6A) has been suggested to increase multiple sclerosis (MS) risk. However, potential interactions between HHV-6A and environmental/lifestyle risk factors for MS have not previously been studied.We used two Swedish population-based case-control studies comprising 5993 cases and 5995 controls. Using logistic regression models, subjects with different HHV-6A antibody levels, environmental exposures, and lifestyle habits were compared regarding MS risk, by calculating odds ratios (ORs) with 95% confidence intervals (CIs). Potential interactions between high HHV-6A antibody levels and common environmental exposures and lifestyle factors were evaluated on the additive scale.High HHV-6A antibody levels were associated with increased risk of developing MS (OR = 1.5, 95% CI = 1.4-1.6). Regarding MS risk, significant interactions were observed between high HHV-6A antibody levels and both smoking (attributable proportion (AP) = 0.2, 95% CI = 0.1-0.3), low ultraviolet radiation (UVR) exposure (AP = 0.3, 95% CI = 0.1-0.4), and low vitamin D levels (AP = 0.3, 95% CI = 0.0-0.6).High HHV-6A antibody levels are associated with increased MS risk and act synergistically with common environmental/lifestyle risk factors for MS. Further research is needed to investigate potential mechanisms underlying the interactions presented in this study.
536 _ _ |a 316 - Infektionen, Entzündung und Krebs (POF4-316)
|0 G:(DE-HGF)POF4-316
|c POF4-316
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a Multiple sclerosis
|2 Other
650 _ 7 |a environmental risk factors
|2 Other
650 _ 7 |a human herpesvirus 6A
|2 Other
650 _ 7 |a interaction
|2 Other
700 1 _ |a Engdahl, Elin
|b 1
700 1 _ |a Gustafsson, Rasmus
|b 2
700 1 _ |a Fogdell-Hahn, Anna
|b 3
700 1 _ |a Waterboer, Tim
|0 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30
|b 4
|u dkfz
700 1 _ |a Hillert, Jan
|b 5
700 1 _ |a Olsson, Tomas
|b 6
700 1 _ |a Alfredsson, Lars
|b 7
700 1 _ |a Hedström, Anna Karin
|0 0000-0002-6612-4749
|b 8
773 _ _ |a 10.1177/13524585211022011
|g p. 135245852110220 -
|0 PERI:(DE-600)2008225-3
|n 3
|p 383-392
|t Multiple sclerosis journal
|v 28
|y 2022
|x 1477-0970
909 C O |p VDB
|o oai:inrepo02.dkfz.de:169184
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-316
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Infektionen, Entzündung und Krebs
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-316
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Infections and cancer
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-27
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2022-11-16
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MULT SCLER J : 2021
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-16
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-16
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MULT SCLER J : 2021
|d 2022-11-16
920 1 _ |0 I:(DE-He78)F022-20160331
|k F022
|l Infektionen und Krebs-Epidemiologie
|x 0
920 1 _ |0 I:(DE-He78)F020-20160331
|k F020
|l Infektionen und Krebs-Epidemiologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F022-20160331
980 _ _ |a I:(DE-He78)F020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21